SecProbe.io

CORRESP
1
filename1.htm

September
13, 2024

VIA
EDGAR

Division
of Corporation Finance

U.S.
Securities & Exchange Commission

100
F Street, NE

Washington,
D.C. 20549

Attention:
Messrs. Dillon Hagius and Tim Buchmiller

Re: Kairos
                                            Pharma, Ltd.

  Registration
                                            Statement on Form S-1

  File
                                            No. 333-274805

Ladies and Gentlemen:

Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), the undersigned,
for itself and the other underwriters, hereby join in the request of Kairos Pharma, Ltd. that the effective date of the above-referenced
registration statement be accelerated so as to permit it to become effective at 9:00 a.m., Eastern time, on Monday, September 16, 2024,
or as soon thereafter as practicable.

Pursuant
to 460 under the Act, we wish to advise you that the underwriters have distributed as many copies of the preliminary prospectus dated
August 16, 2024 to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of such
preliminary prospectus.

The
undersigned advises that it has complied and will continue to comply with the requirements of Rule 15c2-8 under the Securities Exchange
Act of 1934, as amended.

    Very
    truly yours,

    Boustead
    Securities, LLC

    As
    representative of the underwriters

    By:
    /s/
    Lincoln Smith

    Name:
    Lincoln
Smith

    Title:
    Chief
Executive Officer